BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 33905949)

  • 21. Oncolytic Virotherapy: An Advanced Microbial Approach for the Management of Cancer.
    Rao MFS; Ahmed B; Qadir MI
    Crit Rev Eukaryot Gene Expr; 2024; 34(1):1-13. PubMed ID: 37824388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic.
    Zou H; Mou XZ; Zhu B
    Glob Chall; 2023 Jan; 7(1):2200094. PubMed ID: 36618103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combinatorial Approaches for Cancer Treatment Using Oncolytic Viruses: Projecting the Perspectives through Clinical Trials Outcomes.
    Malogolovkin A; Gasanov N; Egorov A; Weener M; Ivanov R; Karabelsky A
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34209981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment.
    Feola S; Russo S; Ylösmäki E; Cerullo V
    Pharmacol Ther; 2022 Aug; 236():108103. PubMed ID: 34954301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Replication-selective oncolytic viruses in the treatment of cancer.
    Everts B; van der Poel HG
    Cancer Gene Ther; 2005 Feb; 12(2):141-61. PubMed ID: 15472714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Live viruses to treat cancer.
    Donnelly O; Harrington K; Melcher A; Pandha H
    J R Soc Med; 2013 Aug; 106(8):310-4. PubMed ID: 23824333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic Virotherapy by HSV.
    Watanabe D; Goshima F
    Adv Exp Med Biol; 2018; 1045():63-84. PubMed ID: 29896663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
    Russell L; Peng KW; Russell SJ; Diaz RM
    BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.
    Yang C; Hua N; Xie S; Wu Y; Zhu L; Wang S; Tong X
    Biomed Pharmacother; 2021 Jul; 139():111573. PubMed ID: 33894623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in oncolytic viral therapy.
    Woo Y; Adusumilli PS; Fong Y
    Curr Opin Investig Drugs; 2006 Jun; 7(6):549-59. PubMed ID: 16784026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncolytic virotherapy.
    Russell SJ; Peng KW; Bell JC
    Nat Biotechnol; 2012 Jul; 30(7):658-70. PubMed ID: 22781695
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncolytic virus immunotherapy: future prospects for oncology.
    Raja J; Ludwig JM; Gettinger SN; Schalper KA; Kim HS
    J Immunother Cancer; 2018 Dec; 6(1):140. PubMed ID: 30514385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy.
    McGrath K; Dotti G
    Hum Gene Ther; 2021 Feb; 32(3-4):150-157. PubMed ID: 33349123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.
    Saito K; Shirasawa H; Isegawa N; Shiiba M; Uzawa K; Tanzawa H
    Oral Oncol; 2009 Dec; 45(12):1021-7. PubMed ID: 19833547
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy.
    Zhang B; Cheng P
    Mol Cancer; 2020 Nov; 19(1):158. PubMed ID: 33172438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncolytic viruses: what to expect from their use in cancer treatment.
    Terrível M; Gromicho C; Matos AM
    Microbiol Immunol; 2020 Jul; 64(7):477-492. PubMed ID: 31663631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A promising future in cancer immunotherapy: Oncolytic viruses.
    Seyed-Khorrami SM; Azadi A; Rastegarvand N; Habibian A; Soleimanjahi H; Łos MJ
    Eur J Pharmacol; 2023 Dec; 960():176063. PubMed ID: 37797673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.